Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma
20 February 2017
Genentech, a member of the Roche Group today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ® (atezolizumab) plus Avastin&
